Sort publications on year

  • Pharmaco-Economics

    Aspects épidémiologiques et économiques de l’insulinothérapie en Fance métropolitaine

    DETOURNAY B

    Med Mal Metab ; (2):149-152

  • Pharmaco-Economics

    Evaluation économique du trastuzumab en traitement adjuvant du cancer du sein précoce surexprimant HER2

    FAGNANI F, COLIN X, ARVEUX P, COUDERT B, MISSET JL

    Bulletin du Cancer ; 94(7):711-720

  • Pharmaco-Economics

    Coût de l’obésité en France

    EMERY C, DINET J, LAFUMA A, SERMET C, KHOSHNOOD B, FAGNANI F

    Presse Med ; 832-840

  • Pharmaco-Economics

    Invasive cervical cancer treatment costs in France

    ARVEUX P, BENARD S, BOUEE S, LAFUMA A, MARTIN L, CRAVELLO L, REMY V, BREUGELMANS JG

    Bull Cancer ; 94(2):219-224

  • Pharmaco-Economics

    Coût de la prise en charge des frottis anormaux et des néoplasies intraépithéliales du col de l’utérus en France

    BERGERON C, COHET C, BOUEE S, LORANS C, REMY V

    BEH ; (1):4-6

  • Pharmaco-Economics

    Costs and effectiveness of travoprost versus a dorzolamide + timolol fixed combination in first-line treatment of glaucoma : analysis conducted on the United Kingdom General Practitioner Research Database

    LAFUMA A, BERDEAUX G

    Curr Med Res Opin ; 23(12):3009-3016

  • Pharmaco-Economics

    Cost Consequences of Adjuvant Capecitabine, Mayo Clinic and de Gramont Regimens for Stage III Colon Cancer in the French Setting

    DOUILLARD JY, TILLEUL P,YCHOU M, DUFOUR P, PERROCHEAU G, SEITZ JF, MAES P, LAFUMA A, HUSSEINI F

    Oncology ; 72:248-254

  • Pharmaco-Economics

    A model of the public health impact of improved treatment persistence in post-meopausal osteoroposis in France

    COTTE FE, CORTET B, LAFUMA A, AVOUAC B, HASNAOUI AE, FADELLONE P, POUCHAIN D, ROUX C, GAUDIN AF

    Joint Bone Spine ; 31

  • Pharmaco-Economics

    Nonmedical economic consequences attribuables to visual impairment nation-wide approach in France

    LAFUMA A, BREZIN A, FAGNANI F, MIMAUD V, MESBAH M, BERDEAUX G

    Eur J Health Econom ; 7(3):158-164

  • Pharmaco-Economics

    Evaluation of non-medical costs associated with visual impairment in four European countries – France, Italy, Germany and the UK

    LAFUMA A, BREZIN A, LAPATRIELLO S, HIEKE K, HUTCHINSON J, MIMAUD V, BERDEAUX G

    Pharmacoeconomics ; 24(2):193-205

  • Pharmaco-Economics

    Estimation of direct unit costs associated with non-vertebral osteoporotic fractures in five European countries

    BOUEE S, LAFUMA A, FAGNANI F, MEUNIER PJ, REGINSTER JY

    Rheumatol Int ; 26(12):1063-72

  • Pharmaco-Economics

    Estimated annual costs of prophylaxis and treatment of venous thromboembolic events associated with major orthopedic surgery in France

    TILLEUL P, LAFUMA A, COLIN X, OZIER Y

    Clin Appl Thromb Hemost ; 12(4):473-484

  • Pharmaco-Economics

    Cervical cancer screening and associated treatment costs in France

    BERGERON C, BREUGELMANS JG, BOUEE S, LORANS C, BENARD S, REMY V

    Gynécol Obstét Fertil ; 34:1036-1042

  • Pharmaco-Economics

    The economic burden of glaucoma and ocular hypertension

    ROULAND JF, BERDEAUX G, LAFUMA A

    Drugs Aging ; 22(4):315-321

  • Pharmaco-Economics

    Dépistage de la rhétinopathie diabétique par des photographies du fond de l’oeil

    AUBERT JP, MASSIN P, AUDRAN G, BEN MEHIDI A, BERNIT B, BOUÉE S, BOUHASSIRA M, BOUROVITCH JC, ERGINAY A, ESCHWÈGE E, JAMET M, MARRE M, NOUGAIREDE M, TCHERNY-LESSENOT S

    RevPrat - Médecine Générale ; 19(692-693):588-592